Payment overview · 2025
General Payments
$1,502.42
80 reported records · 13 companies
Healthcare provider profile · identity verified
Tracy Debiaso, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRIDGETON, NJ · NPI 1831146802
Verified facts
What the public records show
CMS Open Payments records show Tracy Debiaso, MD received $1,502.42 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $527.09 | 35.1% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.66 | 17.4% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.65 | 11.4% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.15 | 5.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.50 | 5.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.72 | 4.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.22 | 4.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.68 | 4.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.79 | 3.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.81 | 2.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.66 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.48 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.01 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,502.42 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $366.30 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $281.85 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $170.65 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.75 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $123.75 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.70 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $87.71 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $83.15 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.68 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.58 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.79 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.58 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.31 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.81 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 124 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 61 |
| Famotidine | Famotidine | 196 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 41 |
| Metformin Hcl | Metformin Hcl | 170 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 47 |
| Omeprazole | Omeprazole | 142 | 37 |
| Potassium Chloride | Potassium Chloride | 126 | 37 |
| Farxiga | Dapagliflozin Propanediol | 124 | 34 |
| Furosemide | Furosemide | 108 | 42 |
| Alprazolam | Alprazolam | 102 | 23 |
| Gabapentin | Gabapentin | 101 | 43 |
| Valsartan | Valsartan | 96 | 36 |
| Tramadol Hcl | Tramadol Hcl | 95 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 31 |
| Simvastatin | Simvastatin | 89 | 25 |
| Allopurinol | Allopurinol | 85 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 27 |
| Montelukast Sodium | Montelukast Sodium | 81 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 11 |
| Mirtazapine | Mirtazapine | 69 | 27 |
| Mounjaro | Tirzepatide | 67 | 16 |
| Atenolol | Atenolol | 63 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 14 |
| Glimepiride | Glimepiride | 61 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 13 |
| Ozempic | Semaglutide | 54 | 13 |
| Lisinopril | Lisinopril | 52 | 16 |
| Losartan Potassium | Losartan Potassium | 52 | 17 |
| Bupropion Xl | Bupropion Hcl | 50 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 15 |
| Eliquis | Apixaban | 49 | 14 |
| Azithromycin | Azithromycin | 47 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Carvedilol | Carvedilol | 40 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Glyxambi | Empagliflozin/Linagliptin | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,502.42 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error